Public Health - Opioid Overdose Reversal Drugs

SB 793 requires healthcare providers issuing standing orders for opioid overdose reversal medications to allow patients to choose any FDA-approved formulation. It prohibits healthcare organizations and clinics from being forced to stock or dispense all FDA-approved opioid reversal drugs. The bill directly affects patients at risk of opioid overdose and healthcare providers or community organizations distributing these medications. This changes existing requirements to increase patient choice while reducing administrative burdens on providers. (SB 793, effective October 1, 2025)